Journal: bioRxiv

Article Title: Regulation of cyanobacterial type IV pilus-dependent functions by interaction between a c-di-GMP receptor and two transcription factors

doi: 10.64898/2026.03.27.713163

Figure Lengend Snippet: A: Volcano plot showing the differentially expressed genes (DEGs) in the ΔcdgR mutant compared to the wild type determined by RNA-seq. DEGs were defined as genes with [log 2 fold change] >1 and log 10 (FDR)<0.05. B-E: Expression of minor pilin genes in the cdgR::Km mutant strain. The cdgR::Km mutant strain was examined for the expression of minor pilin genes. After 24 h of exposure to white-light illumination (75 µmol photons m -2 s -1 ), total RNA was extracted from cells grown in BG11 medium. Three micrograms of RNA were hybridized with radioactively labeled RNA probes targeting the pilA5 mRNA ( B ) and the 5’-UTR of the pilA9 mRNA ( C ). A double-stranded DNA probe that hybridized with Synechocystis 16S rRNA was used as a loading control. Densitometric quantification determined the relative levels of pilA5 ( D ) and pilA9 mRNA ( E ), which were normalized to 16S rRNA levels. Two biological replicates, each with two technical replicates, were performed for the wild type. Four biological replicates, each with two technical replicates, were used for the cdgR::Km mutant experiment.

Article Snippet: Total RNA was extracted, and ribosomal RNA was removed using the Ribo-clean rRNA Depletion Kit (Bacteria) (RN417, Vazyme, Nanjing, China).

Techniques: Mutagenesis, RNA Sequencing, Expressing, Labeling, Control

Journal: Frontiers in Pharmacology

Article Title: Pharmacokinetic/Pharmacodynamic Modeling of Tulathromycin against Pasteurella multocida in a Porcine Tissue Cage Model

doi: 10.3389/fphar.2017.00392

Figure Lengend Snippet: The pharmacokinetic parameters (non-compartmental analysis) of tulathromycin in serum after i.v. or i.m. administration at a dosage of 2.5 mg/kg (mean ± SD, n = 6).

Article Snippet: Tulathromycin standard was purchased from Toronto Research Chemicals (Toronto, ON, Canada).

Techniques:

Journal: Frontiers in Pharmacology

Article Title: Pharmacokinetic/Pharmacodynamic Modeling of Tulathromycin against Pasteurella multocida in a Porcine Tissue Cage Model

doi: 10.3389/fphar.2017.00392

Figure Lengend Snippet: The concentration-time curve for tulathromycin in serum, transudate and exudate after i.m. administration at a dosage of 2.5 mg/kg body weight (for clarity the small graph depicts the drug concentrations in the first 48 h post-administration).

Article Snippet: Tulathromycin standard was purchased from Toronto Research Chemicals (Toronto, ON, Canada).

Techniques: Concentration Assay

Journal: Frontiers in Pharmacology

Article Title: Pharmacokinetic/Pharmacodynamic Modeling of Tulathromycin against Pasteurella multocida in a Porcine Tissue Cage Model

doi: 10.3389/fphar.2017.00392

Figure Lengend Snippet: The pharmacokinetic parameters (non-compartmental analysis) of tulathromycin in exudate and transudate after i.m. administration at a dosage of 2.5 mg/kg (mean ± SD, n = 6).

Article Snippet: Tulathromycin standard was purchased from Toronto Research Chemicals (Toronto, ON, Canada).

Techniques:

Journal: Frontiers in Pharmacology

Article Title: Pharmacokinetic/Pharmacodynamic Modeling of Tulathromycin against Pasteurella multocida in a Porcine Tissue Cage Model

doi: 10.3389/fphar.2017.00392

Figure Lengend Snippet: The concentration-time curve for tulathromycin in serum, transudate and exudate after i.v. administration at a dosage of 2.5 mg/kg body weight (for clarity the small graph depicts the drug concentrations in the first 48 h post-administration).

Article Snippet: Tulathromycin standard was purchased from Toronto Research Chemicals (Toronto, ON, Canada).

Techniques: Concentration Assay

Journal: Frontiers in Pharmacology

Article Title: Pharmacokinetic/Pharmacodynamic Modeling of Tulathromycin against Pasteurella multocida in a Porcine Tissue Cage Model

doi: 10.3389/fphar.2017.00392

Figure Lengend Snippet: The MICs of tulathromycin against P. multocida in MHB and serum.

Article Snippet: Tulathromycin standard was purchased from Toronto Research Chemicals (Toronto, ON, Canada).

Techniques:

Journal: Frontiers in Pharmacology

Article Title: Pharmacokinetic/Pharmacodynamic Modeling of Tulathromycin against Pasteurella multocida in a Porcine Tissue Cage Model

doi: 10.3389/fphar.2017.00392

Figure Lengend Snippet: In vitro time-kill curves for tulathromycin concentration range 0.25-64 MIC against P. multocida CVCC430 in serum.

Article Snippet: Tulathromycin standard was purchased from Toronto Research Chemicals (Toronto, ON, Canada).

Techniques: In Vitro, Concentration Assay

Journal: Frontiers in Pharmacology

Article Title: Pharmacokinetic/Pharmacodynamic Modeling of Tulathromycin against Pasteurella multocida in a Porcine Tissue Cage Model

doi: 10.3389/fphar.2017.00392

Figure Lengend Snippet: In vivo PK/PD integration parameters for tulathromycin after i.v. or i.m. administration and in vitro measurement of MIC (mean ± SD, n = 6).

Article Snippet: Tulathromycin standard was purchased from Toronto Research Chemicals (Toronto, ON, Canada).

Techniques: In Vivo, In Vitro

Journal: Frontiers in Pharmacology

Article Title: Pharmacokinetic/Pharmacodynamic Modeling of Tulathromycin against Pasteurella multocida in a Porcine Tissue Cage Model

doi: 10.3389/fphar.2017.00392

Figure Lengend Snippet: Ex vivo antibacterial activity of tulathromycin against P.multocida in serum (A) , transudate (B) , exudate (C) after i.m. administration at a dosage of 2.5 mg/kg.

Article Snippet: Tulathromycin standard was purchased from Toronto Research Chemicals (Toronto, ON, Canada).

Techniques: Ex Vivo, Activity Assay

Journal: Frontiers in Pharmacology

Article Title: Pharmacokinetic/Pharmacodynamic Modeling of Tulathromycin against Pasteurella multocida in a Porcine Tissue Cage Model

doi: 10.3389/fphar.2017.00392

Figure Lengend Snippet: Integration of pharmacokinetic and pharmacodynamics data obtained for tulathromycin after administration of 2.5 mg/kg in piglets ( n = 6).

Article Snippet: Tulathromycin standard was purchased from Toronto Research Chemicals (Toronto, ON, Canada).

Techniques: Drug discovery

Journal: Frontiers in Pharmacology

Article Title: Pharmacokinetic/Pharmacodynamic Modeling of Tulathromycin against Pasteurella multocida in a Porcine Tissue Cage Model

doi: 10.3389/fphar.2017.00392

Figure Lengend Snippet: The dosage of tulathromycin for achieving corresponding antibacterial effect following i.m. administration.

Article Snippet: Tulathromycin standard was purchased from Toronto Research Chemicals (Toronto, ON, Canada).

Techniques:

Journal: Frontiers in Pharmacology

Article Title: Pharmacokinetic/Pharmacodynamic Modeling of Tulathromycin against Pasteurella multocida in a Porcine Tissue Cage Model

doi: 10.3389/fphar.2017.00392

Figure Lengend Snippet: The pharmacokinetic parameters (non-compartmental analysis) of tulathromycin in exudate and transudate after i.v. administration at a dosage of 2.5 mg/kg (mean ± SD, n = 6).

Article Snippet: Tulathromycin standard was purchased from Toronto Research Chemicals (Toronto, ON, Canada).

Techniques: